Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration

doi: 10.1161/01.atv.0000131654.90788.f5

Figure Lengend Snippet: Figure 3. CCL11 induces mouse SMC chemotaxis. A, Mouse CCL11 in 0.3% FCS at the concentrations indicated (ng/mL) were placed in the bottom wells of a modified Boyden Cham- ber. 104 SMCs were placed in the top wells. The chamber was incubated for 6 hours at 37°C and then analyzed for migration as described in Materials and Methods. For comparison, recom- binant PDGF-BB (1 ng/mL) or 10% FBS were also used as che- moattractants. 0.3% serum was used as negative control. *P0.005 compared with 0 CCL11. B, Checkerboard analysis in which CCL11 (C; 100 ng/mL) was placed in the bottom, top, or both wells as indicated. *P0.005 compared with 0.3% FCS (–). C, SMC were incubated with antibodies against CCR3 (anti- CCR3), CCR2 (anti-CCR2) (1 g/mL), or irrelevant IgG for 30 minutes at 37°C before being placed in the Boyden chamber. Results are expressed as SMC/hpf SEM and represent tripli- cate experiments *P0.005 compared with 0.3% FCS. #P0.05 compared with 0.3% FCS.

Article Snippet: Recombinant mouse CCL11 (420-ME; R & D Systems, Minneapolis, MN) was added to the bottom chamber in 0.3% FBS and DMEM.

Techniques: Chemotaxis Assay, Incubation, Migration, Comparison, Negative Control

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration

doi: 10.1161/01.atv.0000131654.90788.f5

Figure Lengend Snippet: Figure 5. CCL11 does not modulate SMC proliferation. SMCs were plated in 35-mm wells and treated with CCL11 (10 ng/mL or 100 ng.ml) PDGF (1 ng/mL), CCL11 (100 ng/mL) PDGF (1 ng/mL), 10% FCS, or 0.3% FCS. Duplicate plates were counted on the days indicated. The medium, with fresh growth factors, was replaced every 48 hours. Results are expressed as cell number SEM and represent the average of duplicate experiments. Figure 4. CCL11 induces mouse SMC migration. SMCs were grown to confluence and then incubated in DMEM 0.1% BSA for 24 hours. Linear wounds were made in each plate and SMCs were then incubated with DMEM 0.1% BSA alone (con- trol) or in the presence of CCL11 (concentration in ng/mL indi- cated on the X axis). In some experiments, SMCs were preincu- bated for 1 hour with anti-CCR3 (CCR3 Ab) or an irrelevant antibody (IgG) before wounding and treatment with 10 ng/mL CCRL11. The wound area was measured immediately after wounding and at 24 hours. Migration is expressed as the % decrease in wound area in 24 hours compared with control. Experiments were done in duplicate, with 3 to 5 plates used for each condition. *P0.001, 10 ng/mL CCL11 compared with control; **P0.001, 10 ng/mL eotaxin CCR3 Ab compared with 10 ng/mL eotaxin alone; #NS, 10 ng/mL eotaxin IgG compared with 10 ng/mL eotaxin alone.

Article Snippet: Recombinant mouse CCL11 (420-ME; R & D Systems, Minneapolis, MN) was added to the bottom chamber in 0.3% FBS and DMEM.

Techniques: Migration, Incubation, Concentration Assay, Control

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: CCL11 (Eotaxin) Induces CCR3-Dependent Smooth Muscle Cell Migration

doi: 10.1161/01.atv.0000131654.90788.f5

Figure Lengend Snippet: Figure 6. Expression of CCR3 antigen in injured mouse femoral arteries. Samples were obtained from a previous study in which C57Bl/6 mice had undergone wire-induced femoral arterial injury.39 Sections from uninjured arteries (A, B), arteries harvested 5 days (C, D), 7 days (E, F), and 28 days after injury (G through J) were stained with antibodies to CCR 3 (left) or CCL11 (right). Magnifica- tion40 for A, B, E, F, G, and H and 200 for C, D, I, and J. Sections are representative of studies done on 3 different animals.

Article Snippet: Recombinant mouse CCL11 (420-ME; R & D Systems, Minneapolis, MN) was added to the bottom chamber in 0.3% FBS and DMEM.

Techniques: Expressing, Staining

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: cDNA array profiling of genetic alterations and the expression of CCL26 in mono-cultured and co-cultured MG63 cells and hMSCs. ( A ) Changes in mRNA expression in hMSCs at 48 h after the co-culture with MG63 and in MG63 co-cultured with hMSCs. Co-culture condition increased the expression of CCL26 mRNA in both cell lines. ( B ) Relative expression of CCL26 mRNA in alone and co-cultured condition in each cell lines. Changes in the mRNA expression with high expression variability ( C ) and changes in the expression of housekeeping genes (control) ( D ).

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Expressing, Cell Culture, Co-Culture Assay, Control

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: Changes in CCL26 expression and cell growth in MG63 and hMSCs induced by the co-culture condition and rCCL26 administration. ( A ) Changes in CCL26 mRNA expression in MG63 and hMSCs were assessed by qRT-PCR. The co-culture and rCCL26 addition significantly increased the expression of mRNA of CCL26. ( B ) rCCL26 was administered to mono-cultured MG63. There was a significant increase in cell growth with rCCL26 at 10 ng/ml. (*) p < 0.05, (**) p < 0.01. ( C ) Changes in cell proliferation induced by Co-cultured condition and recombinant CCL26 administration in MG63 and hMSCs. ( D ) Changes in the degree of cell proliferation in the untreated, co-culture, and recombinant groups were analyzed by performing cell proliferation assay via BrdU incorporation. ( E ) Changes inCCL26 protein expression of intra-cellular hMSCs and MG63 were assessed by western blot analysis. The co-culture and addition of rCCL26 increased the expression ofCCL26 protein in MG63 and hMSCs. ( F ) The quantification of western blot analysis. Data represents represent the mean ± SD of three independent experiments. p < 0.05 was considered to indicate significance: (*) p < 0.05, (**) p < 0.01.

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Expressing, Co-Culture Assay, Quantitative RT-PCR, Cell Culture, Recombinant, Proliferation Assay, BrdU Incorporation Assay, Western Blot

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: Effects of neutralizing anti-CCL26 Ab on CCL26 expression in mono-cultured and co-cultured MG63 and hMSCs. ( A ) Changes inCCL26 expression in MG63 were assessed by qRT-PCR. The addition of antiCCL26 Ab to MG63 decreased the expression ofCCL26 mRNA. ( B ) Changes inCCL26 expression in hMSCs were assessed by qRT-PCR. The addition of anti-CCL26 Ab to hMSCs decreased the expression ofCCL26 mRNA. ( C ) Changes inCCL26 protein expression in hMSCs and MG63 were assessed by western blot analysis. The addition of anti-CCL26 Ab to MG63 and hMSCs decreased the expression ofCCL26 protein in these cells. ( D ) The quantification of western blot analysis. Data represents represent the mean ± SD of three independent experiments. p < 0.05 was considered to indicate significance: (*) p < 0.05, (**) p < 0.01.

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Expressing, Cell Culture, Quantitative RT-PCR, Western Blot

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: Effects of co-culture condition and administration of rCCL26 or anti-CCL26 Ab on motility of MG63. ( A ) Changes in protein expression of factors related to cell motility. ( B ) The quantification of western blot analysis. Data represents represent the mean ± SD of three independent experiments. ( C ) The influence of co-culture and rCCL26 or anti-CCL26 Ab on actin fiber morphology was evaluated using immunofluorescent imaging. Original magnification, × 400; Scale bars: 50 μm. ( D ) The cell migration of MG63 was assessed in each group at 24 h after the challenge with or without rCCL26 and neutralizing anti-CCL26 Ab. ( E ) The amount of MG63 cells that crossed the membrane was measured. A significant decrease in motility was found in the group given anti-CCL26 Ab. ( F ) The cell invasion in MG63 was assessed in each group after 24 h. ( G ) The amount of the cells of which the membrane with Matrigel was crossed by MG63 was measured. Decreased migration ability was found in the group administered anti-CCL26 Ab. p < 0.05 was considered to indicate significance: (*) p < 0.05, (**) p < 0.01.

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Co-Culture Assay, Expressing, Western Blot, Imaging, Migration, Membrane

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: Changes in expression of Src and its downstream factors related to invasive potential. ( A ) Changes in phosphorylation and the expression of protein factors relating to invasive potential were analyzed. Decreased phosphorylation of Src, FAK, MEK and ERK in MG63 cells was noted in the group administered anti-CCL26 Ab. ( B ) The quantification of western blot analysis. ( C ) Immunofluorescence staining of cultured MG63 cells showed decreased CCL26 and p-Src in the group administered anti-CCL26 Ab. Original magnification, × 400; Scale bars: 50 μm. ( D ) The number of Rac and p-Src positive cells per unit area. Data represents represent the mean ± SD of three independent experiments. p < 0.05 was considered to indicate significance: (*) p < 0.05, (**) p < 0.01.

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Expressing, Phospho-proteomics, Western Blot, Immunofluorescence, Staining, Cell Culture

Journal: Scientific Reports

Article Title: Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma

doi: 10.1038/s41598-021-97153-2

Figure Lengend Snippet: Changes in the lung nodules and the expression of Rac and phosphorylated Src in pulmonary metastatic lesions. ( A ) The group given anti-CCL26 Ab showed a significant suppression of the size of the pulmonary metastatic lesion. ( B ) Immunostaining of the tissues collected from the pulmonary metastatic lesion. Decreased expression of Rac and p-Src was observed in the group administered anti-CCL26 Ab. Original magnification, × 400; Scale bars: 50 μm. ( C ) The number of Rac and p-Src positive cells per unit area. Data represents represent the mean ± SD of three independent experiments. p < 0.05 was considered to indicate significance: (*) p < 0.05, (**) p < 0.01.

Article Snippet: Recombinant human CCL26 (R&D system, USA) (10 ng/ml) was administered to the culture medium.

Techniques: Expressing, Immunostaining

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Comparison of mRNA levels for selected chemokines in the endometrium of pregnant vs. non-pregnant cows as determined by microarray analysis (Fold > 2.0; p < 0.05).

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Comparison, Microarray

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Changes in relative amounts of mRNA for ( a ) CCL2, ( b ) CCL8, ( c ) CCL11, ( d ) CCL14, ( e ) CCL16, and ( f ) CXCL10 in the endometrium at days 15 and 18 of non-pregnant cows (NP) and pregnant cows (P). Data are means ± SEM of four cows per stage and are expressed as relative ratios of the mRNAs to SUZ12 polycomb repressive complex 2 subunit (SUZ12). p -Values show significant differences between NP and P.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 µm.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Negative Control, Control

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Effects of the supernatant derived from homogenized fetal trophoblast (FMP; 200 ng/mL) and interferon-τ (IFNT; 100 ng/mL) on the mRNA expression of ( a ) CCL2, ( b ) CCL8, ( c ) CCL11, ( d ) CCL14, ( e ) CCL16, and ( f ) CXCL10 in cultured bovine endometrial tissues. Homogenization buffer was added at the control group. Data are means ± SEM of five cows and are expressed as relative ratios of the mRNAs to SUZ12. p -Values show significant differences between treated group and control group.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Derivative Assay, Expressing, Cell Culture, Homogenization, Control

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Effects of CCL2, CCL8, CCL11, CCL14, CCL16, and CXCL10 (50 ng/mL each) on the mRNA expression of ( a ) interferon-stimulated gene 15 (ISG15), ( b ) myxovirus-resistance gene 1 (MX1), ( c ) cyclooxygenase 2 (COX2), ( d ) oxytocin receptor (OTR), and ( e ) estrogen receptor α (ESR1) in cultured bovine endometrial tissues. Data are means ± SEM of five cows and are expressed as relative ratios of the mRNAs to SUZ12. p -Values show significant differences between treated group and control group.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Expressing, Cell Culture, Control

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Primers used in real-time PCR.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Sequencing

Journal: International Journal of Molecular Sciences

Article Title: Possible Roles of CC- and CXC-Chemokines in Regulating Bovine Endometrial Function during Early Pregnancy

doi: 10.3390/ijms18040742

Figure Lengend Snippet: Hypothetical model for inhibition of luteolysis by IFNT and chemokines. Although this model is not concerned with the effects of steroids or growth factors, IFNT, CCL2, CCL8, CCL16, CXCL10, and LIF may block TNF-stimulated-COX2 expression in bovine endometrial cells, leading to the reduction of TNF-induced PGF2α output from the cells. Furthermore, IFNT and CCL16 may stimulate anti-viral activity by up-regulating ISG15 and MX1 expression at the time of maternal recognition in cows. Red and blue arrows show stimulatory and inhibitory actions of each substance, respectively. IFNT may stimulate both CCL8 and CXCL10 production and inhibit CCL14 production from bovine endometrium. Effects of CCL11 on bovine endometrial function are still unclear, although its receptor (CCR3) is expressed in the endometrial epithelial cells.

Article Snippet: Cultured endometrial tissues were further incubated in the medium with recombinant proteins as follows: bovine CCL2 (RP0027B, Kingfisher Biotech., Inc. St. Paul, MN, USA), human CCL8 (281-CP, R&D Systems, Inc. Minneapolis, MN, USA), bovine CCL11 (RP0071B, Kingfisher Biotech.), human CCL14 (1578-HC, R&D Systems), human CCL16 (TP723266, OriGene Technologies, Inc., Rockville, MD, USA), bovine CXCL10 (RP0079B, Kingfisher Biotech.), bovine tumor necrosis factor-α (TNF; 2279-BT, R&D Systems), human leukemia inhibitory factor (LIF; TP723270, OriGene Technologies), bovine IFNT (1.1 × 10 5 U/mg, generated from HEK293 cells as described previously; Takahashi et al., 2017 [ ]) or supernatant derived from homogenized fetal trophoblast on day 18 of pregnancy (FMP).

Techniques: Inhibition, Blocking Assay, Expressing, Activity Assay

Journal: mBio

Article Title: Host cysteine proteases promote the severity of catheter-associated urinary tract infection and kidney fibrosis

doi: 10.1128/mbio.02161-25

Figure Lengend Snippet: Eosinophils play a protective role in CAUTI. At 2 dpi, single cells were isolated from the bladder mucosa of CAUTI mice. The percentages of eosinophils and neutrophils were measured by flow cytometry to assess the effects of E64 treatment ( A ) or eotaxin ( B ) as compared to mock. Total CFU recovered 2 dpi were quantified for catheter, bladder, and kidney for treatment by eotaxin ( C–E ), by a-IL-5 ( F–H ), or by CCR3 antagonist SB328437 ( I–K ). Each symbol represents an individual mouse, and symbols touching the dashed lines indicate values below the limit of detection (LOD, 40 CFU). Horizontal lines indicate mean values; error bars represent SEM. All data are from ≥3 biological replicates. Statistical comparisons were performed using a two-tailed unpaired Student’s t-test. * P < 0.05. Normality was assessed using the Shapiro-Wilk test.

Article Snippet: For drug therapy, E64 (Roche, 10874523001), anti-mouse IL-5 (BD Pharmingen, 554393), SB 328437 (CCR3 antagonist, Sigma, 247580-43-4), and mouse eotaxin (R&D systems, 420-ME) were dissolved in PBS according to the manufacturers’ recommendations to achieve the concentration stated in the text.

Techniques: Isolation, Flow Cytometry, Two Tailed Test

Journal: International archives of allergy and immunology

Article Title: Endothelial and epithelial expression of eotaxin-2 (CCL24) in nasal polyps.

doi: 10.1159/000093206

Figure Lengend Snippet: Fig. 1. Localization of CCL24 in nasal tissue. a A representative histologic section of the nasal inferior turbinate stained with anti-CCL24 antibody; neither epithelial nor endothelial cells or other cells were positively stained. Magnifi cation ! 200. b A representative histologic section of nasal polypous tissue obtained from a patient suf- fering from chronic polypous sinusitis accompanied by eosinophilia stained with anti-CCL24 antibody; epithe- lial (arrow 1) and endothelial cells (arrow 2) were strongly stained (dark brown). Magnifi cation ! 200.

Article Snippet: Expression of Eotaxin-2 in Nasal Polyps Int Arch Allergy Immunol 2006;140:205–214 207 Cytokines, Antibodies, and Other Reagents Recombinant human CCL24, TNF- , INF- , and IL-4 were purchased from R&D Systems (Wiesbaden, Germany), peroxidase blocking reagent and 3-amino-9-ethylcarbazole (ACE) as chromogenic substrate from DAKO (DAKO Diagnostics, Hamburg, Germany), and o -phenylenediamine dihydrochloride (OPD) from Sigma (Deisenhofen, Germany).

Techniques: Staining